A study testing whether a GLP-1 medicine from University of Colorado, Denver, semaglutide, can lower blood sugar and help with weight.
What this means for you
- Who can join
- Adults 18 to 49, have type 1 diabetes, BMI 20+.
- What you take
- semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
- How long it lasts
- The full study runs about 4.5 years; your own time in it is usually shorter.
- What you get
- The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
What this study is for
Primary condition: Diabetes Mellitus, Type 1.
Full scientific study title: Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes.
Who can join
Adults 18 to 49, have type 1 diabetes, BMI 20+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Age 18-49 years
- 1) T1D diagnosis defined as positive T1D-associated antibody(ies) or 2) a clinical diagnosis of T1D plus insulin requirement since diagnosis
- Insulin pump or automated insulin delivery systems
- Estimated glomerular filtration rate (eGFR) >= 45 ml/min/1.73m2
- Stable doses of drugs altering cardiovascular and renal function (e.g., Angiotensin-Converting Enzyme Inhibitor (ACEi), Angiotensin Receptor Blocker (ARB), statins, diuretics)
Key exclusion criteria
- HbA1c >9%, recent diabetic ketoacidosis (DKA) or hospitalization
- Major congenital heart disease, anemia, severe non-proliferative retinopathy, proliferative retinopathy
- History/family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2 (MEN2), pancreatitis
- Current/planned pregnancy or nursing
- Uncontrolled thyroid disease or hypertension (HTN) (>= 160/100 mm Hg despite optimal therapy)
Where this study is enrolling
This trial has 2 sites across 2 states. Contact a site coordinator directly to start screening.
Colorado1 site
- University of Colorado Anschutz Medical CampusAurora, Colorado
Washington1 site
- University of Washington Medicine Diabetes Institute (UWMDI)Seattle, Washington
Timeline
Started enrolling: 2023-06-21. Expected completion: 2027-12-01. Last updated on ClinicalTrials.gov: 2026-03-04.
Official source
We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
